NCT03145181 2026-03-12MajesTEC-1Janssen Research & Development, LLCPhase 1/2 Active not recruiting302 enrolled 1 FDA
NCT04067336 2025-11-10First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid LeukemiaKura Oncology, Inc.Phase 1/2 Recruiting263 enrolled 1 FDA
NCT01915498 2024-10-22Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) MutationCelgenePhase 1/2 Completed345 enrolled 120 charts 1 FDA